When will ritixitinib be launched? Has it been launched in China?

Ritlecitinib is a drug used to treat severe alopecia areata (hair loss), with the trade name Litfulo. Ritlecitinib(Ritlecitinib) is a kinase inhibitor that inhibits Januskinase3 and tyrosine kinase. Ritexitinib was approved for medical use in the United States in June 2023 and in the European Union in September 2023. It is currently on the market in China, and the approval time for listing is2023year10month18day.

At present, there is a version officially marketed in Laos. The retail price of Lucius Pharmaceuticals in Laos is more than 50mg28capsules1 more than a thousand. The recommended dose of ritixitinib is 50 mg once daily, with or without food. Swallow capsules whole without crushing, splitting, or chewingritixitinibcapsules. If a dose is missed, take the dose as soon as possible unless it is less than 8 hours before the next dose, in which case skip the missed dose. Thereafter, dosing resumes at normal scheduled times. Rituxitinib is not recommended for patients with severe hepatic impairment (Child Pugh C grade). Ritexitinib is administered orally as 50 mg immediate-release capsules. Each capsule contains 50mg ritritinib (equivalent to 80.13mg ritritinib tosylate) and the following inactive ingredients< /span>:Crosspovidone, glyceryl dibenzoate, lactose monohydrate, microcrystalline cellulose and hypromellose (HPMC) capsule shell. The yellow/blue opaque capsule shell contains bright blueFCF-FD&C blue, hypromellose, titanium dioxide, and yellow iron oxide. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.